8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2009 / Randomized controlled trial (substudy)
In a substudy of the Women's Antioxidant Cardiovascular Study, 2,824 women aged >=65 years were tested 4 times over 5.4 years to evaluate the effects of vitamin E (402 mg alternate days), beta carotene (50 mg alternate days), and vitamin C (500 mg daily). Vitamin E and beta carotene were not associated with slower rates of cognitive change compared to placebo (mean difference in change: -0.01, 95% CI -0.05 to 0.04, P=0.78 for vitamin E; 0.03, 95% CI -0.02 to 0.07, P=0.28 for beta carotene). Vitamin C was associated with better performance at the final assessment (mean difference 0.13, 95% CI 0.06 to 0.20, P=0.0005) but was not associated with cognitive change over time (mean difference 0.02, 95% CI -0.03 to 0.07, P=0.39).
Kang JH, Cook NR, Manson JE, et al. Circulation, 2009. PMID 19451353
2009 / Randomized controlled trial
Fifty-seven Alzheimer's disease patients were randomized to receive placebo or 800 IU of vitamin E daily for six months, with 33 finishing the trial. Among vitamin E-treated patients, respondents showed lower blood oxidized glutathione (GSSG) levels and maintained cognitive test scores. In non-respondents where oxidative stress was not prevented, cognition decreased sharply to levels lower than those taking placebo.
Lloret A, Badía MC, Mora NJ, et al. J Alzheimers Dis, 2009. PMID 19494439
2009 / Randomized controlled trial
Fifty-eight children aged 7 to 9 years were randomly assigned to drink additional water or receive no extra water. Children who consumed extra water rated themselves as significantly less thirsty (p = 0.002). They also scored significantly better on visual attention tasks, including letter cancellation (p = 0.02) and spot-the-difference memory tests (p = 0.019 and p = 0.014).
Edmonds CJ, Burford D Appetite, 2009. PMID 19501780
2009 / Randomized, double-blind, placebo-controlled trial
A 90-day randomized, double-blind, placebo-controlled trial evaluated daily administration of the ketogenic compound AC-1202 in 152 patients with mild to moderate Alzheimer's disease who maintained a normal diet. AC-1202 significantly elevated serum beta-hydroxybutyrate 2 hours post-dose. Compared to placebo, AC-1202 led to a significant difference in mean change from baseline in ADAS-Cog score at Day 45 across the ITT (1.9-point difference, p = 0.0235), per-protocol (2.53-point difference, p = 0.0324), and dosage-compliant (2.6-point difference, p = 0.0215) groups. Improvements were most pronounced in APOE4-negative subjects, showing significant ADAS-Cog differences at both Day 45 and Day 90. Adverse events were more frequent with AC-1202, primarily mild-to-moderate and transient gastrointestinal issues.
Henderson ST, Vogel JL, Barr LJ, et al. Nutr Metab (Lond), 2009. PMID 19664276
2009 / Intervention trial
Researchers evaluated whether drinking water improved performance from baseline to test in twenty-three 6-7-year-old children assigned to a water or no-water group. Significant interactions were observed between test time and water group, showing improvements in the water group for thirst, happiness ratings, visual attention, and visual search. However, no improvements were seen for visual memory or visuomotor performance.
Edmonds CJ, Jeffes B Appetite, 2009. PMID 19835921
2009 / Randomized controlled trial
Researchers randomized 106 overweight and obese adults to an energy-restricted low-carbohydrate or low-fat diet for one year. Both groups achieved similar average weight loss (13.7 kg overall, P = .26) and working memory improvements. However, the low-fat diet led to significantly greater improvements in anxiety, depression, anger, confusion, and total mood disturbance scores compared with the low-carbohydrate diet (P < .05).
Brinkworth GD, Buckley JD, Noakes M, et al. Arch Intern Med, 2009. PMID 19901139
2009 / Placebo-controlled, double-blind trial
A double-blind, placebo-controlled study evaluated the effects of 250 mg or 500 mg daily of BETA 1,3/1,6 GLUCAN compared to placebo over a 4-week post-marathon period in 75 runners. Participants completed the Profile of Mood State (POMS) assessment and a health log measuring URTI symptoms at 2 and 4 weeks. Over the 4-week study, subjects taking either dose of beta-glucan reported significantly fewer URTI symptoms, better overall health, decreased confusion, fatigue, tension, and anger, and increased vigor compared to placebo.
Talbott S, Talbott J J Sports Sci Med, 2009. PMID 24149590
2008 / Randomized crossover imaging trial
Researchers assessed taste pleasantness across a concentration gradient and measured brain responses via functional MRI during administration of 10% sucrose and matched sucralose in 12 healthy women. Both sweeteners activated functionally connected primary taste pathways, and taste pleasantness predicted left insula response. However, sucrose elicited a stronger brain response than sucralose in the anterior insula, frontal operculum, striatum, and anterior cingulate. Additionally, only sucrose stimulation engaged dopaminergic midbrain areas in relation to behavioral pleasantness.
Frank GK, Oberndorfer TA, Simmons AN, et al. Neuroimage, 2008. PMID 18096409
2008 / Double-blind, randomised and placebo-controlled trial
A double-blind, randomized, placebo-controlled trial evaluated whether saffron (30 mg/day; 15 mg twice a day) relieved premenstrual syndrome (PMS) symptoms compared to placebo across two menstrual cycles (cycles 3 and 4) in women aged 20-45 years. Saffron was found to be effective in relieving PMS symptoms. A significant difference was observed in efficacy of saffron in cycles 3 and 4 in the Total Premenstrual Daily Symptoms and the Hamilton Depression Rating Scale.
Agha-Hosseini M, Kashani L, Aleyaseen A, et al. BJOG, 2008. PMID 18271889
2008 / Randomized controlled trial
Researchers evaluated the effect of a realistic dietary dose of L-theanine (50mg) versus placebo on brain function. EEG was recorded in healthy, young participants resting with eyes closed at baseline and 45, 60, 75, 90, and 105 minutes after ingestion (L-theanine n=16, placebo n=19). There was a greater increase in alpha activity across time in the L-theanine condition relative to placebo (p+0.05 [sic]). A second study replicated this effect in participants engaged in passive activity.
Nobre AC, Rao A, Owen GN Asia Pac J Clin Nutr, 2008. PMID 18296328
2008 / Double-blind, randomized, controlled clinical trial
A double-blind trial evaluated the effects of 50 mg daily oral DHEA versus placebo for 1 year in 225 healthy older adults. There were no differences between the DHEA and placebo groups in change over time in cognitive function (P > .10). Over time, BDI scores decreased for men (P = .006) and women (P = .02), and Satisfaction with Life Scale scores increased for women (P = .004), but no differences were observed between the DHEA and placebo groups on these measures, the SF-36, the Life Satisfaction Index-Z scale, or sexual function scales (P > .10).
Kritz-Silverstein D, von Mühlen D, Laughlin GA, et al. J Am Geriatr Soc, 2008. PMID 18482290
2008 / Randomized, double-blind, placebo-controlled crossover trial
Fourteen postmenopausal women completed a randomized, double-blind, placebo-controlled crossover trial receiving 3.5 g/day of powdered Maca and matching placebo for 6 weeks each. No significant differences were observed in serum concentrations of estradiol, FSH, LH, or SHBG between baseline, Maca, and placebo (P > 0.05). However, Maca significantly reduced Greene Climacteric Scale scores for psychological symptoms, including anxiety, depression, and sexual dysfunction compared to baseline and placebo (P < 0.05). Yeast-based assays showed no physiologically significant estrogenic or androgenic activity in Maca extracts.
Brooks NA, Wilcox G, Walker KZ, et al. Menopause, 2008. PMID 18784609
2008 / Double-blind, randomized, parallel-group pilot dose-finding trial
A double-blind pilot study evaluated low-dose (1.5 g/day) versus high-dose (3.0 g/day) maca in 20 remitted depressed outpatients with SSRI-induced sexual dysfunction. In intent-to-treat analyses, subjects on 3.0 g/day showed significant improvements in ASEX scores (from 22.8 +/- 3.8 to 16.9 +/- 6.2; P=0.028) and MGH-SFQ scores (from 24.1 +/- 1.9 to 17.0 +/- 5.7; P=0.017), while those on 1.5 g/day did not. Libido improved significantly based on ASEX item #1 for the ITT and completer groups (P<0.05), but not when analyzed by dosing groups. Maca was well tolerated.
Dording CM, Fisher L, Papakostas G, et al. CNS Neurosci Ther, 2008. PMID 18801111
2008 / Intervention study
Seventeen healthy overweight and obese individuals followed a 3-month reduced-calorie diet with a 25% reduction in energy intake, comprising 55% carbohydrates, 20% proteins, and 25% fat, with no refined sugar. After 3 months, participants experienced significant decreases in BMI, waist circumference, body fat percentage, fasting glucose, post-OGTT glucose, glucose AUC, and HOMA2-IR. Serum BDNF significantly increased from 3.97 +/- 0.87 to 6.75 +/- 1.62 ng/ml (P = 0.02). Final serum BDNF correlated negatively with weight (r = -0.51, P = 0.03) and positively with basal post-OGTT insulin (r = 0.48, P = 0.04).
Araya AV, Orellana X, Espinoza J Endocrine, 2008. PMID 19012000
2008 / Randomized controlled trial
Thirty patients with schizophrenia were randomly allocated to a 10-week aerobic exercise routine performed three days weekly (n = 15) or a control group (n = 15). Relative to controls, participants in the exercise group had significant decreases in positive and negative symptom ratings as well as Brief Symptom Inventory scores. Scores on a standardized quality-of-life assessment also improved after completing the exercise program.
Acil AA, Dogan S, Dogan O J Psychiatr Ment Health Nurs, 2008. PMID 19012672
2008 / Randomized, double-blind, placebo-controlled clinical trial
A randomized, double-blind, placebo-controlled trial evaluated whether 120 mg of Ginkgo biloba extract twice daily reduced incident dementia compared to placebo over a median follow-up of 6.1 years. Overall, 523 participants developed dementia (277 in the G. biloba group and 246 in the placebo group). The hazard ratio for G. biloba compared with placebo was 1.12 (95% CI, 0.94-1.33; P = .21) for all-cause dementia and 1.16 (95% CI, 0.97-1.39; P = .11) for Alzheimer disease. G. biloba also did not alter progression to dementia in participants with mild cognitive impairment (HR, 1.13; 95% CI, 0.85-1.50; P = .39).
DeKosky ST, Williamson JD, Fitzpatrick AL, et al. JAMA, 2008. PMID 19017911
2007 / Randomized controlled trial
Researchers randomized 119 overweight community volunteers to either a low-carbohydrate, ketogenic diet (LCKD) or a low-fat diet (LFD) to evaluate mood, hunger, and other symptoms using the Atkins Health Indicator Test across 12 visits. After adjusting for BMI changes, participants experienced significant improvements in most symptoms on either diet. Significant diet group by visit interactions were found for negative affect [F(9,803) = 2.30, p = 0.015] and hunger [F(9,803) = 3.62, p < 0.0002], with participants in the LCKD group reporting less negative affect and hunger compared to the LFD group.
McClernon FJ, Yancy WS, Eberstein JA, et al. Obesity (Silver Spring), 2007. PMID 17228046
2007 / Randomized controlled trial follow-up
A follow-up study evaluated 52 of 79 healthy term infants previously enrolled in a randomized trial testing formula with DHA and ARA, alongside 32 breastfed children. At four years of age, visual acuity in control formula recipients was poorer than breastfed peers, whereas DHA and DHA plus ARA cohorts did not differ significantly from breastfed children. Verbal IQ was lower than breastfed children in the control and DHA-only groups.
Birch EE, Garfield S, Castañeda Y, et al. Early Hum Dev, 2007. PMID 17240089
2007 / Randomized controlled trial
The Women's Health Initiative trial randomized 36,282 postmenopausal women to receive calcium carbonate 500 mg with vitamin D 200 IU twice daily or placebo for 7 years, evaluating cardiovascular disease as a prespecified secondary outcome. Myocardial infarction or coronary heart disease death occurred in 499 women on calcium/vitamin D and 475 on placebo (HR 1.04; 95% CI 0.92 to 1.18). Stroke was confirmed in 362 women in the calcium/vitamin D group and 377 in the placebo group (HR 0.95; 95% CI 0.82 to 1.10).
Hsia J, Heiss G, Ren H, et al. Circulation, 2007. PMID 17309935
2007 / Randomized single-blind crossover trial
Ten healthy young adults were randomly and single-blind exposed for 30 minutes to mobile phone talk, listen, standby, or sham modes before a 90-minute sleep opportunity. There was no condition effect on subjective ratings of sleepiness. Post-exposure, sleep latency after talk mode was markedly and significantly delayed beyond listen and sham modes, an effect also evident in 1-4Hz frontal EEG power.
Hung CS, Anderson C, Horne JA, et al. Neurosci Lett, 2007. PMID 17548154
2007 / Randomized crossover trial
A double-blind randomized crossover trial examined drinks with sodium benzoate and artificial food color mixes (A or B) or placebo in 153 3-year-olds and 144 8/9-year-olds. Mix A significantly increased global hyperactivity aggregate scores in 3-year-olds compared to placebo (effect size 0.20; 95% CI 0.01-0.39; p = 0.044). In 8/9-year-olds with high protocol adherence, adverse effects occurred with mix A (0.12; 95% CI 0.02-0.23; p = 0.023) and mix B (0.17; 95% CI 0.07-0.28; p = 0.001).
McCann D, Barrett A, Cooper A, et al. Lancet, 2007. PMID 17825405
2007 / Randomized controlled trial
Cognitive testing was added near the close of the beta carotene arm (50 mg, alternate days) of the Physicians' Health Study II to assess general cognition, verbal memory, and category fluency in 5,956 men aged >65 years. Among 1,904 new recruits with a mean treatment duration of 1 year, cognition was similar between beta carotene and placebo groups. Among 4,052 continuing participants with a mean treatment duration of 18 years, the beta carotene group had a significantly higher mean global score (mean difference in z scores, 0.047; P = .03) and verbal memory score (mean difference in z scores, 0.063; P = .007) compared with placebo.
Grodstein F, Kang JH, Glynn RJ, et al. Arch Intern Med, 2007. PMID 17998490
2007 / Double-blind, placebo-controlled crossover trial
In a double-blind, placebo-controlled crossover pilot study, 7 participants with social phobia received either protein-source tryptophan (deoiled gourd seed) combined with carbohydrate or carbohydrate alone, with a 1-week washout between sessions. Protein-source tryptophan with carbohydrate resulted in significant improvement on an objective measure of anxiety, whereas carbohydrate alone did not. The authors conclude that protein-source tryptophan combined with high-glycemic carbohydrate is a potential anxiolytic for social phobia.
Hudson C, Hudson S, MacKenzie J Can J Physiol Pharmacol, 2007. PMID 18066139
2006 / Crossover experimental trial
Researchers measured cardiovascular and respiratory variables in 12 musicians and 12 age-matched controls while they listened to six music styles in random order with a randomly inserted two-minute pause. Faster tempi and simpler rhythmic structures increased ventilation, blood pressure, and heart rate, while decreasing mid-cerebral artery flow velocity and baroreflex compared with baseline. The pause reduced heart rate, blood pressure, and minute ventilation, even below baseline levels. Musicians demonstrated greater respiratory sensitivity to music tempo than non-musicians.
Bernardi L, Porta C, Sleight P Heart, 2006. PMID 16199412